Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers

SIMPLE SUMMARY: BRAF mutant metastatic CRCs (BRAF-mCRCs) are considered a unique clinical entity characterized by a dismal prognosis and that do not respond efficiently to both standard chemotherapy and to orally selective inhibitors of BRAF(V600E). In this study, the gene expression profiles of 89...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolzacchini, Elena, Libera, Laura, Church, Sarah E., Sahnane, Nora, Bombelli, Raffaella, Digiacomo, Nunzio, Giordano, Monica, Petracco, Guido, Sessa, Fausto, Capella, Carlo, Furlan, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405961/
https://www.ncbi.nlm.nih.gov/pubmed/36010943
http://dx.doi.org/10.3390/cancers14163951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405961/
https://www.ncbi.nlm.nih.gov/pubmed/36010943
http://dx.doi.org/10.3390/cancers14163951

Ejemplares similares